Figure 1From: Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot studyEffect of Rituximab therapy on different laboratory and clinical parameters in patients with systemic lupus erythematosus. Twenty-two systemic lupus erythematosus patients with active disease and renal involvement received Rituximab (0.5 to 1.0 g at days 0 and 15), and the (a) disease activity (MEX-SLEDAI index), (b) 24 hour proteinuria, (c) erythrocyturia, and (d) creatinine clearance were measured at days 0, 60, and 90.Back to article page